October 31, 2016
Allergan’s chronic dry eye drops will make patients shed more tears
Allergan has received approval from the FDA for Restasis, treatment to help patients with a type of Chronic Dry Eye …
Pharmaceuticals, Biotechnology and Life Sciences
Category: North America
October 27, 2016
Newly approved drugs push Lilly’s revenues 5% up, but net income went 3% down
The world’s leading drugmaker Eli Lilly saw a decline in net income for the third…
October 25, 2016
Bangladesh’s Beximco gets its second US FDA product approval
Bangladesh-based Beximco, the largest country’s pharmaceutcals exporter, has received its second US FDA …
October 20, 2016
FDA approves Lilly’s Lartruv for soft tissue sarcoma treatment
Eli Lilly and Company announced that FDA has granted approval of LARTRUV (olaratumab injection, 10 mg/mL), in combination with doxorubicin, for the treatment of adults with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.
October 19, 2016
Pfizer’s Inflectra (Chron’s disease) soon available in US
Pfizer will begin shipment of INFLECTRA (infliximab-dyyb) for injection, a biosimilar of REMICADE 1 (infliximab) to wholesalers in the United States (U.S.) in late November 2016.
October 19, 2016
GW Pharmaceutical cancels trading shares on AIM on December 2, 1016, continues trading on NASDAQ
GW Pharmaceuticals plc has announced leaving AIM and canceling trading in London, to continue trading only on NASDAQ.
October 19, 2016
Allergan releases its “lip pumping drug” to the US market
Allergan has announced that the latest addition to the Juvederm collection of fillers, Juvederm Volbella XC, is now available to physicians and patients for use in the lips for lip augmentation and for correction of perioral rhytids, commonly referred to as “lipstick lines”, in adults over the age of 21.
October 14, 2016
Allergan partners with SonarMD in developing new IBS-D patient engagement platform
Allergan has announced a collaboration with SonarMD on the development of clinical decision support (CDS) and patient engagement tools which can be used to facilitate physician identification of patients suffering from Irritable Bowel Syndrome with Diarrhea (IBS-D) in clinical practice and monitor their treatment outcomes.
October 13, 2016
Horizon Pharma offers $300M senior notes and borrows money for buying Raptor Pharmaceuticals
Horizon Pharma, with its wholly owned subsidiaries, Horizon Pharma, Inc. and Horizon Pharma USA, Inc., intends to offer $300 million aggregate principal amount of senior notes due 2024, and to borrow $375 million.
October 9, 2016
New Data on the Combination of Lilly’s ALIMTA and Merck’s KEYTRUDA
Important clinical study results from one of Eli Lilly and Company’s ongoing immuno-oncology collaborations with Merck (known as MSD outside…